<DOC>
	<DOCNO>NCT03016260</DOCNO>
	<brief_summary>RABIOPRED vitro non-invasive blood test , aim identify patient rheumatoid arthritis ( RA ) likely respond anti-TNFα methotrexate combination therapy .</brief_summary>
	<brief_title>RABIOPRED - Validation Study Theranostic Test PREDict Treatment Response Anti-TNFα ( Anti Tumor Necrosis Factor Alpha ) BIologicals Rheumatoid Arthritis</brief_title>
	<detailed_description>Multi-centre , non-interventional , open-label , non-comparative , prospective cohort study clinical follow-up ( ) 12 14 week ( b ) 22 24 week . The RABIOPRED test indicate use patient : - 18 year age old , - Eligible first line biologic therapy anti-TNF alpha . The RABIOPRED test indicate use rheumatologist biological basis guide anti-TNF alpha treatment prior initiation .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<mesh_term>Certolizumab Pegol</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Patient confirm Rheumatoid Arthritis accord American College Rheumatology ( ACR ) classification criterion ( Arnett FC , 1988 , Arthritis Rheum ) Patient DAS28 index great 3.2 . Patient eligible treatment antiTNFα agent ( one Remicade® , Humira® , Enbrel® , Simponi® , Cimzia® , Remsima®/Inflectra® , Benepali® Flixabi® accord `` Summary Product Characteristics '' product ) Methotrexate combination therapy , Patient refractory treatment least one classical DMARDs ( one MTX ) prescribe accord international recommendation , i.e . least 12 week maximal tolerate dose prior antiTNFα treatment dose must keep stable 4 week precede initiation antiTNFα therapy . In case Leflunomide treatment , patient may include study period least 3 month Leflunomide stop , washout cholestyramine least 11 day . Use oral steroid ( ≤ 10 mg/day prednisone equivalent dose another molecule ) and/or NSAIDs permit ; dos must keep stable 4 week precede initiation antiTNFα therapy Patient ( male female ) 18 year age old inclusion , Negative βHCG ( Human Chorionic Gonadotrophin ) pregnancy test , appropriate , accord patient 's age contraceptive method . Written Informed consent sign patient . Patient receive previously antiTNFα biologic therapy molecule development belong antiTNFα class . Patients receive biologics ( antiCD20 , antiCTLA4 , IL1 blocker , IL6 blocker molecule development ) include study period least 6 month , Patient non eligible antiTNFα accord SmPC ( Summary Products ) , Patient antiTNFα monotherapy without methotrexate , Patient clinically significant , severe uncontrolled infectious disease , Patient symptoms significant somatic psychiatric/mental illness , Patient autoimmune disease ( i.e . Inflammatory Bowel Diseases , Systemic Lupus Erythematosus , vasculitis , uncontrolled asthma , etc . ) , Patient evidence cardiac , pulmonary , metabolic , renal , hepatic , gastrointestinal condition , , opinion Investigator , may interfere study , Cancer , Pregnancy , Nursing mother , Patient participate clinical trial biologics period exclusion define</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Rheumatoid Arthritis</keyword>
	<keyword>Anti TNF</keyword>
	<keyword>Infliximab</keyword>
	<keyword>Adalimumab</keyword>
	<keyword>Etanercept</keyword>
	<keyword>Golimumab</keyword>
	<keyword>Certolizumab Pegol</keyword>
	<keyword>Infliximab biosimilar</keyword>
	<keyword>Etanercept biosimilar</keyword>
	<keyword>Methotrexate</keyword>
</DOC>